Status:
COMPLETED
Adjunction of Daptomycin for the Treatment of Pneumococcal Meningitis
Lead Sponsor:
Centre Hospitalier Universitaire Dijon
Conditions:
Pneumococcal Meningitis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Pneumococcal meningitis is an infection of the membrane that covers the brain. It is a serious infection which is currently treated with a combination of corticosteroids (dexamethasone) and 3rd genera...
Eligibility Criteria
Inclusion
- Persons aged over 18 years
- With Suspected pneumococcal meningitis :
- clinical presentation evocative of pneumococcal meningitis : acute onset of ,meningeal signs, history of cranial trauma or fistula, knowledge of alteration of humoral immunity,, asplenia, alcoholism with/or
- clearly purulent CSF with/ or,
- presence of diplococcus on the Gram stain of CSF or positive pneumococcal antigen in the CSF, or polymorphonuclear cells in CSF \> 100
- Written consent or inclusion in an emergency
- Affiliation to a social security system
Exclusion
- Contraindication to cephalosporin
- Immediate and severe hypersensitivity to β-lactam antimicrobial
- Contraindication to dexamethasone
- Contraindication to daptomycin
- Previous exposition to daptomycin (within one year)
- Women who are able to procreate without effective contraception and pregnant or breastfeeding women
- Patients under ward of court
- Refusal at any time after acceptation of the study from the patient or her/his legal representative.
Key Trial Info
Start Date :
June 7 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 21 2024
Estimated Enrollment :
112 Patients enrolled
Trial Details
Trial ID
NCT03480191
Start Date
June 7 2018
End Date
August 21 2024
Last Update
October 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Dijon Bourgogne
Dijon, France, 21000